Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should Be Regarded As AML

Sergej Konoplev,Guilin Tang,Xiaoqiong Wang,Wei Wang,Beenu Thakral,Jie Xu,Sherry A. Pierce,Jeffrey L. Jorgensen,Farhad Ravandi,Ghayas C. Issa,Olga Pozdnyakova,Sa A. Wang,Robert P. Hasserjian
DOI: https://doi.org/10.1182/blood-2021-153749
IF: 20.3
2021-01-01
Blood
Abstract:Introduction: The current World Health Organization (WHO) classification considers acute myeloid leukemia (AML) with PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 to be AML regardless of blast count. Myeloid neoplasms with KMT2A rearrangement present with high blast percentages and are classified as AML in the vast majority of cases; however, rare myeloid neoplasms with KMT2A rearrangement may present with <20% blasts and these are currently considered to be myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). We questioned whether these oligoblastic KMT2A rearranged neoplasms shared similar biology with AML, and if this genetic finding should be considered to be AML-defining.
What problem does this paper attempt to address?